1. Home
  2. TBPH vs AVK Comparison

TBPH vs AVK Comparison

Compare TBPH & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.12

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Logo Advent Convertible and Income Fund

AVK

Advent Convertible and Income Fund

HOLD

Current Price

$12.54

Market Cap

559.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
AVK
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
993.7M
559.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
AVK
Price
$18.12
$12.54
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$27.80
N/A
AVG Volume (30 Days)
516.8K
112.9K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
11.85%
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
N/A
Revenue This Year
$70.78
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.31
N/A
Revenue Growth
27.12
N/A
52 Week Low
$7.90
$9.24
52 Week High
$20.33
$12.16

Technical Indicators

Market Signals
Indicator
TBPH
AVK
Relative Strength Index (RSI) 54.58 47.82
Support Level $17.25 $12.54
Resistance Level $20.32 $12.70
Average True Range (ATR) 0.73 0.14
MACD -0.28 0.02
Stochastic Oscillator 30.62 70.72

Price Performance

Historical Comparison
TBPH
AVK

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About AVK Advent Convertible and Income Fund

Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.

Share on Social Networks: